Last reviewed · How we verify
89Zr-Df-IAB22M2C
At a glance
| Generic name | 89Zr-Df-IAB22M2C |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 89Zr-Df-IAB22M2C CI brief — competitive landscape report
- 89Zr-Df-IAB22M2C updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI